drugset
drugset / Trial / NCT03051607

Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.

NCT03051607 ↗

Phase 3 Terminated 66 enrolled Biotie Therapies Inc. Acorda Therapeutics · collab
NaSingle-groupOpen-labelTreatment

Summary

Phase 3, international, multicenter, open-label 12 month safety study.

Timeline

Start
2017-04-10
Primary completion
2018-01-16
Completion
2018-01-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Tozadenant Small molecule 60 mg —
Subject Tozadenant Small molecule 120 mg —

Indications

Parkinson disease